Overview

  • Product name(-)-Nicotine ditartrate
  • Description
    Potent nAChR agonist
  • Biological descriptionPotent nicotinic acetylcholine receptor (nAChR) agonist. Stimulates autonomic ganglia and skeletal muscle neuromuscular junctions. Reduces beta-amyloidosis in a mouse model of Alzheimer's disease. (Ki values are 16.1 (α4β2), 2110 (α7), 520 (α3β4), 270 (α6/α4β4) and 2090 nM (α1β1γδ)).
  • Purity> 99%

Properties

    References for (-)-Nicotine ditartrate (ab120562)

    This product has been referenced in:
    • Rollema H  et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160:334-45 (2010). Read more (PubMed: 20331614) »
    • Benowitz NL Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57-71 (2009). Read more (PubMed: 18834313) »
    • Coolon RA & Cain ME Individual differences in response to novelty and the conditioned locomotor effects of nicotine. Behav Pharmacol 20:322-9 (2009). Read more (PubMed: 19571743) »
    • Nordberg A  et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81:655-8 (2002). Read more (PubMed: 12065674) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120562.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"